HRP20040303B1 - Use of specific dose of fondaparinux sodium for the treatment of acs - Google Patents

Use of specific dose of fondaparinux sodium for the treatment of acs

Info

Publication number
HRP20040303B1
HRP20040303B1 HR20040303A HRP20040303A HRP20040303B1 HR P20040303 B1 HRP20040303 B1 HR P20040303B1 HR 20040303 A HR20040303 A HR 20040303A HR P20040303 A HRP20040303 A HR P20040303A HR P20040303 B1 HRP20040303 B1 HR P20040303B1
Authority
HR
Croatia
Prior art keywords
acs
treatment
sulfo
specific dose
fondaparinux sodium
Prior art date
Application number
HR20040303A
Other languages
English (en)
Croatian (hr)
Inventor
Wilhelmus Arnold Lensing Anthonie
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8181220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20040303(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HRP20040303A2 publication Critical patent/HRP20040303A2/hr
Publication of HRP20040303B1 publication Critical patent/HRP20040303B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HR20040303A 2001-11-13 2004-03-30 Use of specific dose of fondaparinux sodium for the treatment of acs HRP20040303B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204323 2001-11-13
PCT/EP2002/012482 WO2003041722A1 (en) 2001-11-13 2002-11-07 Use of specific dose of fondaparinux sodium for the treatment of acs

Publications (2)

Publication Number Publication Date
HRP20040303A2 HRP20040303A2 (en) 2004-10-31
HRP20040303B1 true HRP20040303B1 (en) 2012-02-29

Family

ID=8181220

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040303A HRP20040303B1 (en) 2001-11-13 2004-03-30 Use of specific dose of fondaparinux sodium for the treatment of acs

Country Status (37)

Country Link
US (1) US20040248848A1 (xx)
EP (1) EP1446131B1 (xx)
JP (1) JP4523276B2 (xx)
KR (1) KR20050044318A (xx)
CN (1) CN1602197A (xx)
AP (1) AP1820A (xx)
AR (1) AR037291A1 (xx)
AT (1) ATE361753T1 (xx)
AU (1) AU2002351915B2 (xx)
BR (1) BR0212915A (xx)
CA (1) CA2465776A1 (xx)
CO (1) CO5580790A2 (xx)
CY (1) CY1106765T1 (xx)
DE (1) DE60220084T2 (xx)
DK (1) DK1446131T3 (xx)
EA (1) EA007325B1 (xx)
EC (1) ECSP045041A (xx)
ES (1) ES2287343T3 (xx)
GE (1) GEP20074097B (xx)
HK (1) HK1070561A1 (xx)
HR (1) HRP20040303B1 (xx)
HU (1) HU228959B1 (xx)
IL (2) IL161114A0 (xx)
IS (1) IS2484B (xx)
MA (1) MA27071A1 (xx)
ME (2) MEP1108A (xx)
MX (1) MXPA04003045A (xx)
NO (1) NO20041320L (xx)
NZ (1) NZ552129A (xx)
PE (1) PE20030740A1 (xx)
PL (1) PL206008B1 (xx)
PT (1) PT1446131E (xx)
RS (1) RS50906B (xx)
SI (1) SI1446131T1 (xx)
UA (1) UA80399C2 (xx)
WO (1) WO2003041722A1 (xx)
ZA (1) ZA200402464B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075910A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched fondaparinux
AU2016235662B2 (en) * 2015-03-20 2020-07-30 Aarhus Universitet Inhibitors of PCSK9 for treatment of lipoprotein metabolism disorders
US10688249B2 (en) * 2015-06-11 2020-06-23 Virchow Biotech Pvt. Ltd. Multiple dose pharmaceutical compositions containing heparin and/or heparin-like compounds and devices and methods for delivering the same
CN107595769A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种磺达肝癸钠注射液组合物的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU698456B2 (en) * 1997-03-10 1998-10-29 Sanofi-Aventis Compositions containing an association of aspirin and an anti-Xa oligosaccharide and use of anti-Xa oligosaccharide optionally in combination with aspirin
WO1998056365A1 (fr) * 1997-06-13 1998-12-17 Sanofi-Synthelabo INHIBITEUR DU FACTEUR Xa SEUL OU EN COMBINAISON AVEC UN ANTIAGREGANT PLAQUETTAIRE, CONTRE LA THROMBOSE ARTERIELLE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
EP1551852A4 (en) * 2002-04-25 2007-03-21 Momenta Pharmaceuticals Inc METHOD AND PRODUCTS FOR MUCOSAL DELIVERY

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU698456B2 (en) * 1997-03-10 1998-10-29 Sanofi-Aventis Compositions containing an association of aspirin and an anti-Xa oligosaccharide and use of anti-Xa oligosaccharide optionally in combination with aspirin
WO1998056365A1 (fr) * 1997-06-13 1998-12-17 Sanofi-Synthelabo INHIBITEUR DU FACTEUR Xa SEUL OU EN COMBINAISON AVEC UN ANTIAGREGANT PLAQUETTAIRE, CONTRE LA THROMBOSE ARTERIELLE

Also Published As

Publication number Publication date
JP4523276B2 (ja) 2010-08-11
NO20041320L (no) 2004-06-14
ME00229B (me) 2011-10-10
PT1446131E (pt) 2007-08-07
HU228959B1 (en) 2013-07-29
IS7199A (is) 2004-03-29
CN1602197A (zh) 2005-03-30
HK1070561A1 (en) 2005-06-24
MXPA04003045A (es) 2005-06-20
US20040248848A1 (en) 2004-12-09
EA200400382A1 (ru) 2004-10-28
CA2465776A1 (en) 2003-05-22
AP1820A (en) 2008-01-11
HRP20040303A2 (en) 2004-10-31
EP1446131B1 (en) 2007-05-09
HUP0401462A3 (en) 2006-04-28
RS26704A (xx) 2007-02-05
ECSP045041A (es) 2004-04-28
RS50906B (sr) 2010-08-31
AR037291A1 (es) 2004-11-03
KR20050044318A (ko) 2005-05-12
DE60220084T2 (de) 2008-01-10
IS2484B (is) 2008-12-15
PE20030740A1 (es) 2003-08-28
NZ552129A (en) 2008-04-30
GEP20074097B (en) 2007-05-10
IL161114A (en) 2010-11-30
EA007325B1 (ru) 2006-08-25
MEP1108A (en) 2011-02-10
CY1106765T1 (el) 2012-05-23
ATE361753T1 (de) 2007-06-15
PL369027A1 (en) 2005-04-18
DE60220084D1 (de) 2007-06-21
PL206008B1 (pl) 2010-06-30
BR0212915A (pt) 2004-10-13
ZA200402464B (en) 2005-06-29
DK1446131T3 (da) 2007-09-10
EP1446131A1 (en) 2004-08-18
AU2002351915B2 (en) 2007-11-29
AP2004003014A0 (en) 2004-06-30
IL161114A0 (en) 2004-08-31
SI1446131T1 (sl) 2007-10-31
MA27071A1 (fr) 2004-12-20
ES2287343T3 (es) 2007-12-16
HUP0401462A2 (en) 2006-02-28
JP2005509007A (ja) 2005-04-07
WO2003041722A1 (en) 2003-05-22
CO5580790A2 (es) 2005-11-30
UA80399C2 (en) 2007-09-25

Similar Documents

Publication Publication Date Title
NL300385I1 (nl) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases.
CY1107512T1 (el) Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους
HRP20010573B1 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
AU2002243387A1 (en) Pharmaceutical dosage form for oral administration of low molecular weight heparin
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
UY25544A1 (es) Forma de dosificación de nefazodona
SE0101932D0 (sv) Pharmaceutical combinations
NO994431L (no) Ny formulering
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
SE9700885D0 (sv) New pharmaceutical formulation
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
IS2258B (is) Setin tríasóló-pýridasín afleiða, lyfjasamsetningar gerðar úr henni
PL360492A1 (en) Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates
HRP20040303B1 (en) Use of specific dose of fondaparinux sodium for the treatment of acs
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
BRPI9916820B8 (pt) composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv
DK1423109T3 (da) Præparater som omfatter pektin og ascorbinsyre
NO20032411L (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
SE9902742D0 (sv) New pharmaceutical formultion
ATE425731T1 (de) Pharmazeutische zusammensetzungen eines nichtmagensaftresistenten protonenpumpen-hemmers mit einer carbonat- und bicarbonatsalzkombination
BR0316123A (pt) Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: SANOFI-AVENTIS, FR

PPPP Transfer of rights

Owner name: GLAXO GROUP LIMITED, GB

B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: GLAXO GROUP LIMITED, GB

PPPP Transfer of rights

Owner name: ASPEN GLOBAL INCORPORATED, MU

ODRP Renewal fee for the maintenance of a patent

Payment date: 20181030

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20191029

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20201102

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20211021

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20221107